Phigenics Secures Battery Majority Investment for Water Safety

Phigenics has received a strategic majority-growth investment from Battery Ventures, moving a 22-year-old water-management company from founder-built independence into institutional majority ownership. The parties announced the transaction on September 17, 2026, but did not disclose the amount, valuation, exact ownership percentage, leverage, or other financial terms.

The useful story is the operating loop Battery is buying. Phigenics combines water-management program design, cloud software, continuous sensors, laboratory testing, documentation, and corrective-action support for facilities where a water-quality failure can become a compliance problem, an operational disruption, and a patient-safety event.

Phigenics reports serving more than 250 customer organizations, including major hospital systems, Department of Veterans Affairs facilities, and ambulatory surgery centers. Battery General Partner Zack Smotherman and Principal Max-Julian Kaye will join the board, while Mark Crockett, MD, remains CEO with the existing management team.

What Phigenics and Battery Ventures Announced

The companies describe the deal as a majority-growth investment. Battery's portfolio record classifies Phigenics as an active 2026 buyout-stage investment, which makes the transaction more than a passive financing even though the ownership mechanics remain private. Phigenics says the partnership will support investment in new and existing products, expanded capabilities, and entry into additional markets.

Bill McCoy, Ashton McCombs, and Jay Reading founded Phigenics in Naperville, Illinois, in 2004. The company later moved its headquarters and one laboratory to Warrenville, Illinois, while adding a laboratory in Fayetteville, Arkansas. Mark Crockett became CEO in August 2024 after more than 20 years in emergency medicine and leadership roles across healthcare technology and services.

The transaction keeps management continuity while changing the capital and governance around the business. Smotherman leads later-stage and buyout investing in Battery's industrial-technology and life-science-tools practice. Kaye focuses on late-stage software and industrial technology. Both will take board seats, placing the investor directly inside the decisions about products, markets, operating capacity, and any future expansion.

A Water Sample Is Only One Handoff

Building water risk changes with temperature, disinfectant residual, water age, stagnation, construction, equipment, occupancy, and the vulnerability of the people using the facility. A laboratory result can establish what a sample contained at one moment, but the facility still needs a program that identifies hazards, assigns control measures, monitors conditions, documents exceptions, and proves that corrective action occurred.

Phigenics built across those handoffs. Its water-management programs help facilities map systems, identify hazards, set controls, and maintain program documentation. phiAnalytics centralizes reports, tasks, alerts, and enterprise oversight. Automated sensors measure indicators including disinfectant residual, temperature, and pH, feeding trend data and out-of-parameter alerts into the software.

The company's validation-testing operation adds culture and molecular methods for Legionella and panels for additional microbial hazards. Phigenics says its laboratories are CDC ELITE-certified and offer ISO 11731 culture testing, next-day molecular screening, viable-but-non-culturable Legionella detection, and gene-sequencing-based speciation. Those are company-described capabilities rather than independently benchmarked outcomes, but they show why the business is broader than a software subscription or a testing lab.

Healthcare Turns Water Management Into Continuing Work

CDC guidance says healthcare water-management programs should bring together facility managers, infection-prevention professionals, clinicians, administrators, and other specialists. The work includes mapping building water systems, evaluating hazardous conditions, locating control measures, intervening when control limits are missed, validating that the program works, and documenting the activity.

CMS guidance expects covered hospitals, critical access hospitals, and long-term-care facilities to maintain policies and procedures that reduce the growth and spread of Legionella and other opportunistic waterborne pathogens. Facilities must conduct risk assessments, specify control measures and testing protocols, document results, and record corrective actions. ANSI/ASHRAE Standard 188 supplies minimum legionellosis risk-management requirements for building water systems.

That operating burden explains the commercial attraction more clearly than an undisclosed check. A provider that remains involved across design, monitoring, testing, software, reporting, and remediation can become part of the customer's compliance machinery. The relationship is reinforced each time a facility adds a building, encounters an exception, prepares for a survey, or tries to standardize a program across a portfolio.

What Battery Is Buying Into

Battery says it has invested in water-related technology businesses for more than 20 years, including analytical testing, instrumentation, and sensors. Phigenics pulls those categories into one service relationship, giving the investor exposure to recurring scientific work, installed monitoring equipment, software-supported oversight, and the people who help customers interpret the data.

The majority position also changes the standard Phigenics will be measured against. The company must keep scientific credibility and customer trust while making a complex, people-intensive operating model more repeatable. Healthcare remains the center of gravity, but the announcement names hospitality and retail as expansion markets, each with different facilities, occupants, risk profiles, and decision makers.

Phigenics' more-than-250-customer figure is useful evidence of an established base, but it is company-reported. The parties did not disclose revenue, profitability, retention, contract duration, facility count, customer concentration, or independently audited health outcomes. Battery's investment thesis therefore rests on a visible operating model and private diligence that public readers cannot fully inspect.

The Questions the Announcement Leaves Open

The transaction does not disclose how much capital goes onto the balance sheet, whether founders or management sold shares, how much equity they retained, whether debt was used, or whether acquisitions are part of the plan. It also leaves the product roadmap, hiring targets, geographic priorities, and market-expansion timetable undefined.

Those gaps matter because majority ownership can fund several different playbooks. Battery could support organic product investment, more laboratories and field capacity, broader sales coverage, entry into adjacent industries, or acquisitions that add technical capabilities and customer relationships. The announcement commits only to products, capabilities, reach, and new markets, so anything more specific would outrun the evidence.

Phigenics now has an investor that understands the economics of testing, instrumentation, sensors, and tech-enabled services. The work ahead sits inside the same handoff the company has sold since 2004: turning a measurement into a decision, assigning that decision to people, and preserving enough evidence to show what happened before water risk becomes somebody else's emergency.